Skip to main content
Premium Trial:

Request an Annual Quote

Affibody Enters Imaging Agent Research Collaboration with GE Healthcare

NEW YORK, June 19 (GenomeWeb News) - Affibody said today that it has begun a research collaboration with GE Healthcare to develop imaging agents for applications in personalized medicine. 

 

Affibody will provide its Affibody molecules for three disease targets defined by GE Healthcare. The Affibody molecules will be developed for targeted in vivo imaging applications, Affibody said.

 

GE Healthcare has the exclusive option to license the molecules for development and commercialization as imaging agents, while Affibody retains rights for use of the molecules outside the scope of in vivo diagnostic and medical imaging.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.